Patent ID: 7736905
Filing Date: 2010-06-15
Classification: A61P,G06K,G16B,Y02A,Y10T

Abstract:
1. A method of identifying a non-small cell lung cancer patient as being likely to benefit from treatment with gefitinib or erlotinib targeting an epidermal growth factor receptor pathway or not likely to benefit from treatment with gefitinib or erlotinib, comprising the steps of: a) obtaining a mass spectrum from a blood-based sample from the non-small cell lung cancer patient; b) performing one or more predefined pre-processing steps on the mass spectrum obtained in step a); c) obtaining integrated intensity values of selected features in said spectrum at one or more predefined m/z ranges after the pre-processing steps on the mass spectrum in step b) have been performed; d) using the values obtained in step c) in a classification algorithm using a training set comprising class-labeled spectra produced from blood-based samples from other on-small cell lung cancer patients to identify the patient as being either likely or not likely to benefit from gefitinib or erlotinib.